Harvard Update on Severe Asthma 2026

$150.00

One-time payment
Lifetime access

Instant
download

Lifetime
access

Secure
checkout

SKU: MS-32722 Categories: Harvard Medicine, Internal Medicine, Pulmonary /Respiratory Tags: 2024 Updates, ACQ AQLQ, adult severe asthma, allergic bronchopulmonary aspergillosis course, allergy immunology course, and Tools to Improve Patient Care, asthma biologics training, asthma case discussions CME, asthma clinical training 2026, Asthma courses, asthma education program Harvard, asthma guidelines, asthma immunology genetics course, asthma management 2025, asthma management course 2026, asthma precision medicine course, benralizumab, biologics for asthma, biologics in asthma therapy, biomarkers FeNO IgE eosinophils, Board, Brigham Women Hospital asthma course, bronchial thermoplasty, CME, CME asthma online course, CME course pulmonology, difficult-to-treat asthma, dupilumab, eosinophilic asthma, eosinophilic asthma treatment, exacerbation reduction, GINA 2025 updates, GINA guidelines asthma, harvard, harvard board review, harvard cme, harvard courses 2024, Harvard Internal Medicine Comprehensive Review, Harvard INTERNAL MEDICINE Comprehensive Review and Update, Harvard Internal Medicine Comprehensive Review and Update 2022, Harvard INTERNAL MEDICINE Comprehensive Review and Update 2024, Harvard INTERNAL MEDICINE Comprehensive Review and Update 2025, harvard internal medicine in 2024, Harvard medical courses online, Harvard pulmonology course, Harvard Severe Asthma 2026, Harvard Update on Severe Asthma, Harvard Update on Severe Asthma 2025, Harvard Update on Severe Asthma 2026, ICS LABA LAMA, internal medicine board review, internal medicine cme, mepolizumab, NAEPP asthma guidelines, nasal polyps asthma, obesity and asthma, occupational asthma training, omalizumab, pediatric asthma management course, pediatric severe asthma, pulmonology board review asthma, severe asthma CME course, Severe Asthma course, severe asthma phenotypes, severe asthma treatment strategies, SMART therapy, spirometry FEV1, steroid-sparing strategies, Strategies, tezepelumab, triple therapy asthma, Type 2 inflammation, Updates in General Internal Medicine for Specialists, Updates in General Internal Medicine for Specialists 2024

Description

Pulmonary & RespiratoryVideo course2026

Harvard Update on Severe Asthma 2026 — biologics, remission and the difficult-to-control patient

The Harvard Update on Severe Asthma 2026 is Brigham and Women’s two-day course on asthma that won’t settle, recorded 16–17 March 2026 and supplied as videos with PDFs. Elliot Israel leads a faculty that includes Tanya Laidlaw, Benjamin Raby, James Chalmers and Ian Pavord through phenotypes and diagnostics, AERD, occupational and paediatric asthma, bronchiectasis overlap, choosing among biologics, clinical remission and the comorbidities that keep patients uncontrolled.

25sessions
2course days
2case-discussion panels
Mar 2026recorded

What you’ll be able to do

Confirm the diagnosis and phenotype severe asthma accurately
Choose and switch between biologics — and understand bi- and tri-specific antibodies
Aim for clinical remission rather than symptom control
Manage AERD, eosinophilic lung disease and bronchiectasis overlap
Address obesity, smoking, anxiety and depression as drivers of poor control

Inside the course

Harvard Update on Severe Asthma 2026, day one: diagnosis
Key recent papers, airway biology, diagnostic assessment, AERD, primary prevention, occupational exposures, genetics and environment, severe asthma in children, bronchiectasis and the PreCISE precision-medicine trial, ending with diagnostic cases.
Day two: treatment
Eosinophilic inflammation, next-generation antibodies, choosing a biologic, remission, psychiatric comorbidity, eosinophilic lung disease, paediatric care, obesity and diabetes, smoking and COPD, anti-inflammatory rescue and population health, ending with treatment cases.

Built for

Pulmonologists and allergistsAdvanced management of refractory asthma.
Internists and paediatriciansWhen to suspect severe disease and refer.
ENT specialistsUpper-airway disease and AERD.

Faculty & programme

Day 1 — Monday, March 16 13 sessions

Conversations in Severe Asthma (Biologic Treatment – Eosinophilic Phenotype)
Elliot Israel — Welcome and Introduction
Benjamin Medoff, Nora Barrett — “Can’t Miss Articles” in Severe Asthma
Benjamin Medoff — Asthma Insights: The View from the Airways
Nora Barrett — Diagnostic Assessment of Severe Asthma
Tanya Laidlaw — Managing Asthma with Aspirin-Exacerbated Respiratory Disease
Akenroye, Phipatanakul, Weiss, Nadeau — Panel: Primary Prevention of Asthma
Robert McCunney — Occupational Exposures and Severe Asthma
Benjamin Raby — Asthma Genetics & Environment
Jonathan Gaffin — Severe Asthma in Children
James Chalmers — Bronchiectasis & Asthma Overlap
Steve Georas — Precision Medicine (PreCISE Trial)
Panel — Case Discussions (Diagnosis)

Day 2 — Tuesday, March 17 12 sessions

Fasenra & Eosinophilic Inflammation
Ayobami Akenroye — Bi & Tri-Specific Antibodies
Elliot Israel — Choosing Among Biologics
Ian Pavord — Clinical Remission in Asthma
E. Sherwood Brown — Asthma, Anxiety & Depression
Joshua Boyce — Eosinophilic Lung Disease
Sejal Saglani — Severe Asthma in Children
Dinah Foer — Obesity, Diabetes & Asthma
Carrie Pistenmaa — Smoking, COPD & Asthma
Nancy Lange-Vaidya — Anti-Inflammatory Rescue
Ayobami Akenroye — Biologics & Population Health
Panel — Case Discussions (Treatment)

Before you buy

Do I get CME credit or a certificate?

No. Clinicapedia provides the educational content only — no CME or CE credits, MOC points or certificates of completion are included with this product.

Specifications

Format	HD videos + PDF slides
Contents	25 sessions over 2 days
Recorded	16–17 March 2026
Course director	Elliot Israel, MD
Publisher	Brigham and Women’s Hospital
Department	Pulmonary & Respiratory
Delivery	Instant download · lifetime re-download